- Home
- SGLY vs CERO Comparison
SGLY vs CERO Comparison
Compare SGLY & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- CERO
- Stock Information
- Founded
- SGLY 2001
- CERO 2017
- Country
- SGLY United States
- CERO United States
- Employees
- SGLY N/A
- CERO N/A
- Industry
- SGLY
- CERO
- Sector
- SGLY
- CERO
- Exchange
- SGLY Nasdaq
- CERO Nasdaq
- Market Cap
- SGLY 3.4M
- CERO 3.6M
- IPO Year
- SGLY 2008
- CERO N/A
- Fundamental
- Price
- SGLY $0.69
- CERO $1.83
- Analyst Decision
- SGLY
- CERO Strong Buy
- Analyst Count
- SGLY 0
- CERO 2
- Target Price
- SGLY N/A
- CERO $45.00
- AVG Volume (30 Days)
- SGLY 320.7K
- CERO 430.6K
- Earning Date
- SGLY 10-14-2025
- CERO 11-18-2025
- Dividend Yield
- SGLY N/A
- CERO N/A
- EPS Growth
- SGLY N/A
- CERO N/A
- EPS
- SGLY N/A
- CERO N/A
- Revenue
- SGLY $1,813,193.00
- CERO N/A
- Revenue This Year
- SGLY N/A
- CERO N/A
- Revenue Next Year
- SGLY N/A
- CERO N/A
- P/E Ratio
- SGLY N/A
- CERO N/A
- Revenue Growth
- SGLY N/A
- CERO N/A
- 52 Week Low
- SGLY $0.54
- CERO $1.81
- 52 Week High
- SGLY $5.49
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- SGLY 36.09
- CERO 19.85
- Support Level
- SGLY $0.67
- CERO $1.81
- Resistance Level
- SGLY $0.85
- CERO $2.58
- Average True Range (ATR)
- SGLY 0.06
- CERO 0.34
- MACD
- SGLY 0.00
- CERO -0.02
- Stochastic Oscillator
- SGLY 18.59
- CERO 0.82
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.